More than 30 years ago it was discovered that permeability glycoprotein (P-gp) can cause drug resistance. Over the following decades numerous studies showed that high expression of P-gp is associated with poor prognosis in acute myeloid leukemia in adults and that it causes multidrug resistance via ATP-dependent drug efflux. It was hoped that an inhibition of P-gp could sensitize resistant leukemic cells to chemotherapy and thus improve treatment results. Today we know that the family of ATP-binding cassette transporters (ABC transporters) comprises 48 different proteins. Some of them seem to be able to cause drug resistance as well as P-gp. This review focuses on emerging data on the clinical relevance of other ABC transporters, such as BCRP, MRP3, and ABCA3. When Heracles fought the ancient Hydra, he had to fight all the heads at ones but only one head was vital for the beast. Can we block all the relevant ABC transporters at once? Is there one transporter that is more important than the others?
Introduction
A major issue in the treatment of acute leukemia is resistance to chemotherapeutic drugs. Some patients fail to respond to chemotherapy and others relapse with resistant disease.
In 1976 Juliano and Ling 1 described a protein that was associated with reduced drug permeability in Chinese hamster ovary cells. The protein was named permeability glycoprotein (P-gp). Six years later it was shown that a similar protein exists and confers multidrug resistance in human cells. 2 In 1986, Chen et al. 3 provided first evidence that P-gp is an energy-dependent efflux pump. Marie et al. 4 reported that the expression of P-gp was associated with a poor outcome in patients with acute myeloid leukemia (AML).
These findings initiated a great hype. It was hoped that P-gp would be the major cause of drug resistance and that this finding would lead the way to new therapeutic strategies in malignant diseases.
Today we know that P-gp is one of 48 different human ATPbinding cassette transporters (ABC transporters). 5 ABC transporters facilitate ATP-dependent transport of various substrates via extra-or intracellular membranes. All ABC transporters that are able to transport cytostatic drugs might cause drug resistance in the same way as P-gp. There are two main lines of evidence for clinical relevance of an ABC transporter.
First, in vitro studies show that the transporter can efflux cytostatic drugs and confer resistance to these drugs in cell cultures. Second, the expression of the transporter in patient samples is associated with poor response to therapy.
This review focuses on the second line of evidence and summarizes in vitro data on those transporters that seem to be associated with poor response to therapy in acute leukemia. Studies that only analyzed ABC transporters as part of highdensity microarrays were not taken into account since these techniques are not sensitive and specific enough to allow conclusions about individual ABC transporters. The strong homology in this large family of proteins necessitates specially designed and validated low-density arrays to analyze the clinical relevance of individual ABC transporters. 5, 6 P-glycoprotein (ABCB1)
The best-characterized ABC transporter is the P-gp, which is encoded by the multidrug resistance gene 1 (MDR1 or ABCB1). In vitro it confers resistance to many drugs, which are used in the treatment of acute leukemia such as doxorubicin, daunorubicin, vincristine, vinblastine, methotrexate, mitoxantrone and others. 7 Numerous studies have confirmed that the expression of P-gp is an adverse prognostic factor for complete remission and survival in adult AML. 4, [8] [9] [10] [11] [12] [13] However, in future studies it should be taken into account that this association is age-dependent. In two large studies, Leith et al.
9,10 could show that the prognostic impact of P-gp is more pronounced in elderly patients with AML than in young adults with AML. In pediatric patients it does not have a prognostic impact at all. 14, 15 There could be two reasons for this age dependence. First, the expression of P-gp is higher in older individuals. 16 Second, pediatric treatment protocols tend to be more aggressive. Thus, the expression of P-gp in younger patients might not be strong enough to cause clinically relevant drug resistance and/or drug resistance could be overcome by more intensive treatment.
In acute lymphoblastic leukemia (ALL), the picture is similar. Most of the studies that analyzed pediatric ALL found no significant association between P-gp and prognosis.
11, [17] [18] [19] In a few other studies P-gp correlated with poor response to therapy. 20, 21 This discrepancy might be due to different treatment strategies. The expression of P-gp in adult patients is higher than in children 22 and in this age group a prognostic impact was consistently reported. [23] [24] [25] [26] Breast cancer resistance protein (ABCG2)
The breast cancer resistance protein (BCRP) is one of the more recently discovered ABC transporters. It was isolated from multidrug-resistant MCF7/ADRVp breast cancer cells. 27 BCRP is encoded by the ABCG2 gene, which was mapped to chromosome 4. 28 It has only one ATP-binding cassette and six putative transmembrane domains, suggesting that BCRP is a halftransporter. 29 High expression of BCRP has been described in drug-resistant ovary, breast, colon, gastric cancer and fibrosarcoma cell lines. 30 In vitro, it confers resistance to a wide range of drugs that are used in the treatment of acute leukemia such as daunorubicin, etoposide, methotrexate, mitoxantrone and others. 7 So far, five studies were published that analyzed the association between expression of BCRP and response to therapy in AML. Each study pointed towards a prognostic impact of BCRP. Benderra et al., 12 Steinbach et al., 31 and Uggla et al. 32 analyzed BCRP mRNA; Damiani et al. 33 analyzed BCRP protein expression and in a second study Benderra et al. 34 analyzed protein expression as well as protein function. In each study, higher levels of BCRP expression or function were associated with a lower chance of survival. Three studies also described significantly higher levels of BCRP in patients who failed to achieve remission.
12, 31, 34 In summary, there is little doubt that BCRP correlates with poor prognosis in adult AML 12,32-34 and probably also in childhood AML. 31 Little is known about the role of BCRP in ALL. The expression is lower in T-ALL than in precursor B-ALL; 35, 36 it is also lower in infant ALL than in older patients. 37 One small study found a trend for worse outcome in adult patients with higher levels of BCRP, 38 and in another such study in pediatric patients no such association was found. 36 Multidrug resistance-associated protein 1 (ABCC1)
The ABC-C subfamily of ABC transporters encodes the multidrug resistance-associated proteins (MRP). The first member of this subfamily, MRP1, was described in 1992 by Cole et al. 39 It is overexpressed in many multidrug-resistant human cancer cell lines and confers resistance to a wide range of drugs, which are used in the treatment of acute leukemia, for instance doxorubicin, daunorubicin, vincristine, etoposide and methotrexate. 7 Many studies have analyzed the clinical relevance of MRP1 in AML. The results are very controversial. Many studies reported a correlation between MRP1 and poor prognosis. 8, 13, 40, 41 An equally large number found no such correlation.
9,42-44 There are a number of possible explanations for these findings. Many different methods were used to study MRP1 expression such as PCR, flow cytometry, western blot, immunocytochemistry or functional assays. This is particularly relevant since many of these methods were established before the other members of the ABC-C subfamily were discovered. As a consequence, some of the analyses were probably not as specific for MRP1 as they were meant to be. Even if one tries to compare studies that used similar methods for the detection of MRP1, the results are still inconsistent. This might be due to different treatment regimens or patient characteristics. For example, the results are controversial in patients treated with anthracyclines and cytarabine, but two studies confirmed the role of MRP1 overexpression in resistance to treatment with gemtuzumab ozogamicin. 45, 46 In conclusion, there seems to be some degree of correlation between MRP1 and poor prognosis. However, if MRP1 was a major determinant of drug resistance in AML, this correlation should be found more consistently.
In ALL, the data are even less suggestive for a relevant prognostic impact of MRP1. Most studies found no correlation between MRP1 and poor prognosis.
18,19,25
Multidrug resistance-associated protein 3 (ABCC3) Besides MRP1, there exist 11 other members of the ABC-C subfamily of ABC transporters. 7 Many of them were shown to be able to efflux cytostatic drugs. Only few studies have analyzed the prognostic relevance of these proteins in leukemia but each study found that MRP3 is associated with a lower chance of survival. This was the case for children with AML, 47 adults with AML, 34 children with ALL 48, 49 and adults with ALL. 49 This finding was independent of the method used for the detection of MRP3. Benderra et al. 34 analyzed protein expression as well as protein activity. Steinbach et al. 47, 48 and Plasschaert et al. 49 analyzed gene expression. Based on this limited number of studies it seems that MRP3 is the only ABC transporter, which correlates with poor prognosis in AML and in ALL independent of the patient age. However, in vitro data are less suggestive of a major role of MRP3 in drug resistance. MRP3 was shown to cause resistance against etoposide, teniposide, and methotrexate. 50, 51 So far, it seems that other important leukemia drugs are no substrates for MRP3. 7 Plasschaert et al. 49 also found a prognostic relevance for MRP2, MRP4 and MRP5 in their group of ALL patients. This was not the case in other studies.
ABCA3
The latest ABC transporter, which was correlated with response to chemotherapy in acute leukemia is ABCA3. Yasui et al. 52 found that a number of drug-resistant cancer cell lines showed higher copy numbers of the ABCA3 gene and a stronger expression of the gene compared to the drug-sensitive parental cell lines. Hirschmann-Jax et al. 53 showed that ABCA3 and BCRP are expressed in various malignant stem cells and that the two genes together might be involved in the resistance of these cells against mitoxantrone.
Norwood et al. 54 described the expression of ABCA3 in an in vivo propagated human AML cell line. The same group could show that the protein ABCA3 was expressed in a panel of AML samples. 55 Using a low-density microarray for ABC transporters it could be shown that ABCA3 is overexpressed in pediatric AML compared to healthy bone marrow and that its expression is associated with a poor response to remission induction therapy. 56 The prognostic impact of ABCA3 in pediatric AML was confirmed by Chapuy et al. ABCA3 is located at intracellular membranes. 57 Its does not confer a 'classical' drug efflux but rather seems to be involved in the intracellular sequestration and the vesicular transport of its physiological substrates as well as chemotherapeutic agents such as daunorubicin. 55, 57 ABCA3 is also expressed in ALL. 58 Its association with response to therapy in this form of leukemia has not yet been examined.
Summary
P-gp and BCRP were shown to be associated with poor response to chemotherapy in adult AML (Table 1) . Both proteins confer resistance to a wide range of chemotherapeutic drugs in vitro. It is very likely that P-gp and BCRP play a causative role in drug resistance in adult AML. Therefore, they represent possible therapeutic targets. In pediatric AML, this seems to be the case for BCRP but not for P-gp. In ALL, both proteins appear to be less relevant with the probable exception of P-gp in adult patients.
MRP3 has a strong prognostic impact in AML and ALL independent of age group. However, MRP3 does not cause much drug resistance in vitro. Therefore, it remains to be elucidated whether its correlation with poor response to therapy is causative or an epiphenomenon. If MRP3 turns out to be a real cause of drug resistance, it would be the ABC transporter with the widest therapeutic spectrum in acute leukemia.
ABCA3 might be an additional cause of drug resistance in AML. It seems to be associated with in vitro drug resistance and response to therapy but both aspects need further studies for verification.
Future perspectives
A number of clinical trials were aimed at improving outcome in patients with AML by inhibiting P-gp. The overall results are not encouraging. [59] [60] [61] [62] [63] However, it is too early to conclude that such a strategy is not feasible. It is difficult to find the right inhibitor with the right dosing and at the same time a dose reduction of chemotherapy may be necessary because of drug interactions. In addition, in most studies the patients were included irrespective of their P-gp status. For example, in Becton's study, 59 only 14% of patients overexpressed P-gp. Under these conditions, it is not possible to show a statistically significant impact of P-gp inhibition in P-gp-positive patients. In the same way in Solary's study, 61 there was no difference between patients treated or not with quinine (a modulator of P-gp) in the total group, but in the subgroup of 54 P-gp-positive patients quinine significantly improved the CR rate from 12 of 25 (48.0%) to 24 of 29 (82.8%) (P ¼ 0.01). Interestingly, the study that showed the strongest benefit of P-gp inhibition in AML was one of those that used cyclosporine as inhibitor. 62 Cyclosporine is a broad-spectrum inhibitor of ABC transporters. 64 It affects P-gp as well as BCRP, MRP1, ABCB11 and ABCC10. Whether it also affects MRP3 or ABCA3 remains to be clarified.
Many inhibitors of P-gp are also effective against BCRP. 7 Future clinical trials in AML should use such inhibitors and they should be restricted only to adult patients who express a functional ABC protein. In adult ALL it would make sense to test inhibitors, which are more specific for P-gp. They are likely to show fewer side effects and the current knowledge does not provide a good rational to target other ABC transporters. 
